0001004878-14-000150.txt : 20140418
0001004878-14-000150.hdr.sgml : 20140418
20140417180738
ACCESSION NUMBER: 0001004878-14-000150
CONFORMED SUBMISSION TYPE: 8-K
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20140417
ITEM INFORMATION: Entry into a Material Definitive Agreement
FILED AS OF DATE: 20140418
DATE AS OF CHANGE: 20140417
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: CEL SCI CORP
CENTRAL INDEX KEY: 0000725363
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 840916344
STATE OF INCORPORATION: CO
FISCAL YEAR END: 0930
FILING VALUES:
FORM TYPE: 8-K
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-11889
FILM NUMBER: 14770994
BUSINESS ADDRESS:
STREET 1: 8229 BOONE BLVD .
STREET 2: SUITE 802
CITY: VIENNA
STATE: VA
ZIP: 22182
BUSINESS PHONE: 7035069460
MAIL ADDRESS:
STREET 1: 8229 BOONE BLVD.
STREET 2: SUITE 802
CITY: VIENNA
STATE: VA
ZIP: 22182
FORMER COMPANY:
FORMER CONFORMED NAME: INTERLEUKIN 2 INC
DATE OF NAME CHANGE: 19880317
8-K
1
form8koverallot4-14.txt
FORM 8-K ITEM 1.01 OVER-ALLOTMENT
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (date of earliest event reported): April 17, 2014
CEL-SCI CORPORATION
----------------------------------------------
(Exact name of Registrant as specified in its charter)
Colorado 01-11889 84-0916344
-------------------- ------------------------ ----------------------
(State or other jurisdiction (Commission File No.) (IRS Employer
of incorporation) Identification No.)
8229 Boone Boulevard, Suite 802
Vienna, Virginia 22182
---------------------------------------------------
(Address of principal executive offices, including Zip Code)
Registrant's telephone number, including area code: (703) 506-9460
N/A
-----------------------------------------
(Former name or former address if changed since last report)
Check appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below)
[ ] Written communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-14(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Item 1.01 Entry into a Material Definitive Agreement.
On April 14, 2014 CEL-SCI Corporation (the "Company"), Dawson James
Securities, Inc. and Laidlaw & Company (UK) Ltd. (the "Underwriters"), entered
into an underwriting agreement (the "Underwriting Agreement") to issue and sell
shares of the Company's common stock, as well as warrants to purchase shares of
common stock, for the combined purchase price of $1.40. Each warrant entitles
the holder to purchase one share of the Company's common stock at a price of
$1.58 per share. The warrants expire on October 17, 2014.
The offering of the 7,128,229 shares and the 1,782,057 warrants closed on
April 17, 2014. The net proceeds to the Company from the sale of the shares and
warrants was approximately $9,230,000, after deducting the underwriting
discount.
The shares and warrants were offered and sold pursuant to the Company's
existing shelf registration statement on Form S-3 (333-186103) that was declared
effective by the Securities and Exchange Commission on February 28, 2013, a
Prospectus dated December 17, 2013 and a Prospectus Supplement dated April 14,
2014.
The foregoing description of the Underwriting Agreement is not complete
and is qualified in its entirety by reference to the full text of the
Underwriting Agreement, a copy of which was filed as Exhibit 1 to the Company's
Report on Form 8-K dated April 14, 2014, and is incorporated by reference
herein.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Date: April 17, 2014
CEL-SCI CORPORATION
By:/s/ Geert Kersten
--------------------------------
Geert Kersten, Chief Executive
Officer